Avalo Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Avalo Therapeutics

03/08/2023 14:25

* Avalo Therapeutics Inc  AVTX.OQ  reported a quarterly
adjusted
loss of 59 cents​​ per share for the quarter ended in June. The
mean expectation of two analysts for the quarter was for a loss
of 80 cents per share.
    * Revenue fell 37.8% to $643.00 thousand from a year ago;
analysts
expected $500.00 thousand. 
    * Avalo Therapeutics Inc's reported EPS for the quarter was
a loss
of 59 cents​.
    * The mean earnings estimate of analysts had risen by
about 11.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Avalo Therapeutics Inc shares had fallen by 43.7% this
quarter and lost 96.0% so far this year.
    * The company reported a quarterly loss of $8.19 million.
    * Wall Street's median 12-month price target for Avalo
Therapeutics Inc is $0.75 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 3 at 01:24 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.80          -0.59          Beat
 Mar. 31 2023      -0.97          -0.85          Beat
 Dec. 31 2022      -0.73          -1.04          Missed
 Sep. 30 2022      -1.09          0.34           Beat